IFNB1 and myeloid sarcoma: Although evidence suggests that the development of NAbs can adversely affect IFNβ efficacy, we suggest that NAbs-positivity explains the poor response to IFNβ treatment only in a small proportion of patients with MS and their appearance should be weighted against other factors hampering the response to treatment.